This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Merck (MRK) Stock Moves -0.06%: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $78.83, marking a -0.06% move from the previous day.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
5 Small-Cap ETFs to Profit From the January Effect
by Sweta Killa
After registering double-digit annual growth, Wall Street is poised to gain from the historical trend of January Effect.
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RYH)?
by Zacks Equity Research
Sector ETF report for RYH
Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
Genprex's (GNPX) Lead Cancer Drug Gets Second Fast Track Tag
by Zacks Equity Research
The FDA bestows a Fast Track designation to Genprex's (GNPX) Reqorsa in combination with Keytruda for treating patients with non-small cell lung cancer. This is the second Fast Track tag for Reqorsa.
Here's Why Pfizer (PFE) Appears Strongly Placed for 2022
by Kinjel Shah
While the COVID vaccine should continue to boost Pfizer (PFE) revenues in 2022, Paxlovid is also likely to become an important top-line driver
Is Invesco S&P 500 Equal Weight Health Care ETF (RYH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RYH
Merck (MRK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $77.14, marking a +0.25% move from the previous day.
Can-Fite (CANF) Files Patent Applications for Namodenoson
by Zacks Equity Research
Can-Fite (CANF) files patent applications in several countries for treating all advanced solid tumors. The filing comes after Can-Fite's drug cleared all tumor lesions in advanced liver cancer.
5 Sector ETFs That Crushed the Market in December
by Sweta Killa
With just a few trading sessions left to end December, the S&P 500 index has gained 4.8%. A few sector ETFs have outperformed.
Can Veklury Sales Retain Momemtum for Gilead (GILD) in 2022?
by Zacks Equity Research
Solid sales from Veklury cushion Gilead (GILD) in 2021 amid COVID-19. However, new oral antivirals in the market might hurt sales. GILD now shifts focus to oncology as the virology space faces issues.
Stock Market News for Dec 27, 2021
by Zacks Equity Research
U.S. stocks closed higher for the third consecutive day on Thursday, with the S&P 500 hitting a record high ahead of a long Christmas holiday weekend as investors shed fears and felt more optimistic that the Omicron variant of the coronavirus won¿¿¿t affect global economy growth.
The Zacks Analyst Blog Highlights: Tesla, Adobe, Merck, Edwards Lifesciences and Norfolk Southern Corp
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Tesla, Adobe, Merck, Edwards Lifesciences and Norfolk Southern Corp
Merck's (MRK) COVID Pill Gets FDA Nod for Emergency Use
by Zacks Equity Research
Merck's (MRK) oral antiviral molnupiravir secures the FDA-authorized emergency use tag in treating mild-to-moderate COVID-19 in adults for whom other FDA-approved COVID treatments are unsuitable.
Pharma Stock Roundup: FDA Approves PFE & MRK's Oral Pills for COVID & Other Drugs
by Kinjel Shah
FDA approves Pfizer's (PFE) and Merck's (MRK) oral COVID antiviral pills and AstraZeneca's (AZN) asthma medicine, Tezspire (tezepelumab).
Top Stock Reports for Tesla, Adobe & Merck
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Tesla, Inc. (TSLA), Adobe Inc. (ADBE), and Merck & Co., Inc. (MRK).
Pfizer (PFE) Gets FDA's Emergency Use Nod for COVID Pill
by Zacks Equity Research
Pfizer's (PFE) COVID-19 pill Paxlovid is the first oral antiviral medicine, which can be prescribed as an at-home treatment for mild-to-moderate COVID-19.
Stock Market News for Dec 23, 2021
by Zacks Equity Research
Wall Street closed higher on Wednesday completing back-to-back rallies after three-days of Omicron-led decline.
Merck (MRK) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $76.16, marking a +0.82% move from the previous day.
Seagen (SGEN) Gets Positive CHMP Opinion for Bladder Cancer Drug
by Zacks Equity Research
The CHMP gives a positive opinion on, and recommends approval to Seagen's (SGEN) Padcev as a monotherapy for treating adult patients with locally advanced/metastatic urothelial cancer.
Pfizer (PFE) COVID Pill Paxlovid Gets CHMP Support in Europe
by Zacks Equity Research
The CHMP supports the use of Pfizer's (PFE) oral COVID-19 drug, Paxlovid, to treat high-risk patients even though it has not received conditional authorization from the European Commission.
Pharma Stock Roundup: PFE Announces Arena Buyout, LLY Ups 2021 View & More
by Kinjel Shah
Pfizer (PFE) offers to buy Arena Pharmaceuticals. Lilly (LLY) raises 2021 profit and sales outlook.
Merck (MRK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $75.91, marking a +0.82% move from the previous day.
Merck's (MRK) Pneumococcal Vaccine Vaxneuvance Gets EU Nod
by Zacks Equity Research
Merck's (MRK) Vaxneuvance includes pneumococcal serotypes 22F and 33F, which are not included in the currently licensed 13-valent conjugate vaccines.